VHPB meeting:
WHO: where will we make a difference

HIV/AIDS DEPARTMENT – HEPATITIS PROGRAMME

Stefan Wiktor
Team Lead, Global Hepatitis Programme
Making a difference

• WHO actions guided by WHA resolution (2010 and 2014) mandates
• Strategic directions guided by actions in the Global Hepatitis Strategy (assuming it is adopted by World Health Assembly 2015)
Actualizing World Health Assembly Resolution WHA67.6

• National planning:
  – support countries to develop robust national viral hepatitis strategies
  – provide guidance on cost-effective ways to integrate the prevention, testing, care and treatment of viral hepatitis into existing health care systems

• Strategic information:
  – develop a system for regular monitoring and reporting on the progress in viral hepatitis prevention, diagnosis and treatment;
  – estimate global, regional and domestic economic impact and burden of viral hepatitis
  – examine the feasibility of and strategies needed for the elimination of hepatitis B and hepatitis C with a view to potentially setting global targets;
Actualizing World Health Assembly Resolution WHA67.6

• Laboratory Diagnosis:
  – develop specific guidelines on adequate, effective, affordable algorithms for diagnosis;

• Blood safety:
  – promote safe donation from low-risk voluntary non-remunerated donors, counselling, referral and treatment of infected donors, and effective blood screening;

• Promote access to prevention and treatment services:
  – lead a discussion and work with key stakeholders
  – assist Member States to ensure equitable access
  – promote access to harm-reduction services
  – provide technical assistance in the use of TRIPS flexibilities
What do we want to accomplish

• Position WHO as leader in hepatitis response
• Support countries with comprehensive hepatitis programmes and plans
• Strategic information
• Immunization
• Prevention of infections in health-care settings
• Enhance treatment access
Priority actions:
Focus on strategic information

• Issue Surveillance Guidance and provide technical assistance
• Develop monitoring indicators and guidance
• Begin to issue global hepatitis reports
• Develop operational research agenda
Priority actions:
Normative work for treatment

• Continue to develop treatment guidelines that will inform national treatment programs
  • Hepatitis testing guidelines
    – HCV treatment updates
• Consolidated hepatitis guidelines
  – Service delivery considerations
  – End-stage liver disease management
Actions to enhance treatment access

- Inclusion of key hepatitis drugs in Essential Medicines List:
  - daclatasvir, sofosbuvir, sofosbuvir/ledipasvir, ombitasvir/paritaprevir/ritonavir/plus-minus dasabuvir, entecavir,

- Expression of Interest Letter for prequalification of generics

- Providing key data on medicines:
  - HCV medicines patent landscape
  - Inclusion of hepatitis medicines and diagnostics in Global Price Reporting Mechanism
  - Adapting ARV toxicity monitoring systems to collect information on hepatitis medicines
Priority actions: Prevention

• Injection safety:
  – promote implementation of Global Injection Safety Policy
  – Promote expansion of harm-reduction interventions
• HBV: promote novel measures to enhance HBV birth dose administration and to identify new interventions to prevent mother-to-child transmission
• Blood safety: quality assured testing of all blood donations
Priority actions:
Engagement with countries

• Identify priority countries
• Finalize National Planning tool-kit and distribute to countries
• Regional and national workshops to assist country implementation